Monoclonal antibodies (mAbs) are a crucial asset for human health and modern medicine,
however, the repeated administration of mAbs can be highly immunogenic. Drug …

Tumor necrosis factor inhibitors (TNFi) have significantly improved treatment outcome of
rheumatic diseases since their incorporation into treatment protocols two decades ago …

Immune responses to protein and peptide drugs can alter or reduce their efficacy and may
be associated with adverse effects. While anti-drug antibodies (ADA) are a standard clinical …

Hypersensitivity reactions (HSRs) to monoclonal antibodies (mAbs) are increasingly
frequent as this class of therapeutic agents is rapidly expanding. Immediate and …

Biologicals are crucial targeted therapeutic agents in oncological, immunological, and
inflammatory diseases, and their use in clinical practice is broadening. In recent years, the …

The chimeric antibodies anti-CD20 rituximab (Rtx) and anti-TNFα infliximab (Ifx) induce
antidrug antibodies (ADAs) in many patients with inflammatory diseases. Because of the key …

In silico immunogenicity risk assessment has been an important step in the development
path for many biologic therapeutics, including monoclonal antibodies. Even if the source of a …

Introduction: Anti-tumor necrosis factor (TNF) agents have changed the therapeutic
approach to inflammatory bowel disease (IBD). However, a considerable proportion of …

Immunogenicity assessment of therapeutic proteins is routinely performed through various
techniques during the drug development process:(i) in silico to design the least …

Therapeutic antibodies can elicit unwanted immune responses in a subset of patients, which
leads to the production of anti-drug antibodies (ADA). Some of these ADAs have been …